Tesema Getayeneh Antehunegn, Stirling Rob G, Wah Win, Tessema Zemenu Tadesse, Heritier Stephane, Earnest Arul
School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne 3168, Australia; Department of Respiratory Medicine, Alfred Health, Melbourne 3004, Australia.
Lung Cancer. 2025 Jan;199:108077. doi: 10.1016/j.lungcan.2024.108077. Epub 2025 Jan 4.
Delayed surgery is significantly associated with an increased risk of disease progression and adverse outcomes in lung cancer. Evidence is available on the variation in delayed surgical treatment among patients with Non-Small Cell Lung Cancer (NSCLC). However, the relative contribution of patient- and area-level risk factors to the geographic patterns of delayed surgery in patients with NSCLC is poorly understood. Therefore, we aimed to explore the geographic variation in delay to surgical treatment among patients with NSCLC.
This study utilized data from the Victorian Lung Cancer Registry (VLCR) and the Australian Bureau of Statistics (ABS). A total of 3,088 patients with NSCLC who had undergone surgery were included. We applied a Bayesian spatial multilevel model incorporating spatially structured and unstructured random effects to examine patient and area-level risk factors associated with delays to surgical treatment. Model comparison was conducted using the Deviance Information Criterion (DIC).
Over one-third (40.45 %) of NSCLC patients experienced delayed surgical treatment. Significant geographic variation in delayed surgical treatment among NSCLC patients across Local Government Areas (LGAs) was observed. Factors significantly associated with higher odds of delayed surgical treatment included clinical stage II (AOR = 1.56, 95 % CrI: 1.26-1.92), stage III (AOR = 1.90, 95 % CrI: 1.46-2.47), stage IV (AOR = 2.04, 95 % CrI: 1.15-3.61), treatment at inner regional hospitals (AOR = 2.86, 95 % CrI: 2.17-3.70), presence of comorbidities (AOR = 1.19, 95 % CrI: 1.02-1.40), and diagnosis during the COVID-19 pandemic (AOR = 1.32, 95 % CrI: 1.10-1.57).
This study highlights the need to improve the treatment pathway for patients with NSCLC by reducing the time between diagnosis and surgery. Future targeted initiatives are essential to promote timely surgeries for NSCLC patients, especially in high-need areas.
延迟手术与肺癌疾病进展风险增加及不良预后显著相关。关于非小细胞肺癌(NSCLC)患者延迟手术治疗的差异已有相关证据。然而,患者层面和地区层面的风险因素对NSCLC患者延迟手术地理模式的相对贡献尚不清楚。因此,我们旨在探讨NSCLC患者手术治疗延迟的地理差异。
本研究利用了维多利亚肺癌登记处(VLCR)和澳大利亚统计局(ABS)的数据。共纳入3088例接受手术的NSCLC患者。我们应用了一个包含空间结构化和非结构化随机效应的贝叶斯空间多层次模型,以检查与手术治疗延迟相关的患者和地区层面的风险因素。使用偏差信息准则(DIC)进行模型比较。
超过三分之一(40.45%)的NSCLC患者经历了延迟手术治疗。观察到NSCLC患者在地方政府区域(LGAs)之间延迟手术治疗存在显著的地理差异。与延迟手术治疗几率较高显著相关的因素包括临床II期(调整后比值比[AOR]=1.56,95%可信区间[CrI]:1.26-1.92)、III期(AOR=1.90,95%CrI:1.46-2.47)、IV期(AOR=2.04,95%CrI:1.15-3.61)、在内城区医院接受治疗(AOR=2.86,95%CrI:2.17-3.70)、存在合并症(AOR=1.19,95%CrI:1.02-1.40)以及在COVID-19大流行期间确诊(AOR=1.32,95%CrI:1.10-1.57)。
本研究强调需要通过缩短诊断与手术之间的时间来改善NSCLC患者的治疗路径。未来有针对性的举措对于促进NSCLC患者及时手术至关重要,尤其是在需求较高的地区。